MariMed Reports Third Quarter 2022 Earnings

Download as PDF

Related Documents

NORWOOD, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- MariMed, Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2022.

“I am pleased to report we grew revenue both year-over-year and sequentially, despite continued headwinds facing the entire industry,” said Bob Fireman, Chief Executive Officer. “MariMed continues to outperform these industry dynamics on the strength of our outstanding retail and wholesale operations, high quality and innovative product mix, and exceptional customer service.”

Financial Highlights1

The following table summarizes the consolidated financial highlights for the three months ended September 30, 2022 and 2021 (in millions, except percentage amounts):

  Three months ended
September 30,
    2022       2021  
Revenue $ 33.9     $ 33.2  
Gross margin   48 %     55 %
GAAP Net income $ 2.7     $ 2.1  
Non-GAAP Adjusted EBITDA $ 8.6     $ 12.6  
Non-GAAP Adjusted EBITDA margin   25 %     38 %

1 See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” in the attached schedules.

CONFERENCE CALL
MariMed management will host a conference call on Tuesday, November 8, 2022, to discuss these results at 8:00 a.m. Eastern time. The conference call may be accessed through MariMed’s Investor Relations website by clicking the following link: MariMed Q322 Earnings Webcast.

THIRD QUARTER OPERATIONAL HIGHLIGHTS

During the third quarter, the Company announced the following facets of its strategic growth plan, including:

  • July 18: The approval of its expanded state-of-the-art kitchen in Maryland. The nearly ten-fold expansion allows the Company to produce all its award-winning branded products including Betty’s Eddies fruit chews, Bubby’s Baked baked goods, K Fusion chewable tablets, and Vibations High + Energy powdered drink mixes. The Company also introduced a line of gummies in the Maryland medical cannabis market, under the In-House brand.
  • August 4: The launch of its new Betty’s Eddies ice cream in partnership with Boston-based Emack & Bolio’s® ice cream company. Betty’s Eddies ice cream is currently available in select cannabis dispensaries in Massachusetts.
  • August 8: The acquisition of a conditional dispensary license in central eastern Illinois close to the Indiana border. Once open, it will mark the fifth Thrive branded dispensary the Company owns and operates in Illinois. MariMed currently owns and operates four adult-use dispensaries in Anna, Harrisburg, Metropolis, and Mt. Vernon.
  • August 30: The launch of its Nature's Heritage "LIVE Flower," the freshest cannabis available. The unparalleled freshness is made possible through MariMed's proprietary FreshCure curing process, which delivers buds that are bigger and brighter than conventional flower, bursting with more vibrant colors and stronger aromas while delivering a smoother smoke.
  • September 12: The agreement to develop and manage a state-of-the-art production kitchen to manufacture and wholesale its award winning branded products in Missouri. Voters are expected to approve an adult use measure on the ballot this fall, and the Company expects its branded products will be available on the wholesale market before adult-use sales commence.
  • September 13: The agreement with 42 Degrees, a Michigan licensed cannabis producer and distributor, to manufacture and distribute MariMed’s award-winning brands and products throughout the state. 42 Degrees currently wholesales products into 340 dispensaries, representing approximately 75 percent of the operating dispensaries in Michigan.

OTHER BUSINESS DEVELOPMENTS

Subsequent to the end of the third quarter, the Company announced the following business developments:

  • October 5: The opening of its first medical dispensary in Annapolis, Maryland, marking the beginning of the Company's fully vertical operations in that state. The Panacea Wellness dispensary is the eighth retail location across four states that MariMed either owns or manages. MariMed hosted a grand opening ceremony with several local, county, and state dignitaries in attendance to celebrate commencement of operations. Voters are expected to approve an adult use measure on the ballot this fall and MariMed expects to build out its footprint in Maryland to include the maximum allowable four dispensaries over time.
  • October 25: The evolution of its award-winning and top-selling Betty's Eddies fruit chews line to address consumer demand for cannabis edibles that meet specific needs. Each new or improved chew has been custom formulated to help aid sleep, relaxation, pain relief, heightened libido, and more.

"We remain bullish for continued revenue and earnings growth,” said Jon Levine, President. “Fueling our confidence are several new and expanded assets in our existing markets that will come online in 2023. Additionally, we look forward to our entry next year into additional high-growth cannabis markets, including Ohio, Missouri, and Michigan.”

2022 FINANCIAL GUIDANCE

MariMed remains committed to its proven strategic growth plan and continues to operate some of the best cannabis facilities with some of the highest margins and returns in the cannabis industry. Due to continued regulatory delays with opening dispensaries, the Company's guidance for full year 2022 has been revised and is as follows:

  • Revenue of $132 million to $135 million.
  • Gross margin of 48% to 49%.
  • Non-GAAP Adjusted EBITDA of $32 million to $35 million.
  • Capital expenditures of $16 million to $17 million.

“Our financial results remain some of the best in the industry, as we have improved gross margins and delivered positive adjusted EBITDA for the eleventh consecutive quarter,” said Susan Villare, Chief Financial Officer. “Our ability to generate positive cash flow from operations in this challenging macro environment is a testament to the outstanding asset base that MariMed has developed and maintained.”

DISCUSSION OF NON-GAAP FINANCIAL MEASURES

The Company has provided in this release several non-GAAP financial measures: Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, as a supplement to Revenue, Gross margin, and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as net income, determined in accordance with GAAP, excluding the following items:

  • interest income and interest expense;
  • income taxes;
  • depreciation of fixed assets;
  • amortization of acquired intangible assets;
  • Impairment or write-downs of intangible assets;
  • stock-based compensation;
  • legal settlements;
  • acquisition-related and other;
  • other income and other expense;
  • and discontinued operations.

For further information, please refer to the Company’s Quarterly Report on Form 10-Q for the three month period ended September 30, 2022 available on MariMed's Investor Relations website, on the SEC’s Edgar website in the U.S., or on the Canadian securities regulatory authorities’ SEDAR website in Canada.

ABOUT MARIMED
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.

IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This release contains certain forward-looking statements and information relating to MariMed Inc. that are based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current view of the Company with respect to future events, including consummation of pending transactions, launch of new products, expanded distribution of existing products, obtaining new licenses, estimates and projections of revenue, EBITDA and Adjusted EBITDA and other information about its business, business prospects and strategic growth plan, which are based on certain assumptions of its management, including those described in this release. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional risk factors are included in the Company’s public filings with the Securities and Exchange Commission. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “planned, “estimated,” “preparing,” “potential,” “expected,” “looks” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

All trademarks and service marks are the property of their respective owners.

For More Information Contact:

Investor Relations:
Steve West, Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007

Media Contact:
Trailblaze PR
Email: marimed@trailblaze.co

Company Contact:
Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007


MariMed Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

  September 30,
2022		   December 31,
2021
Assets      
Current assets:      
Cash and cash equivalents $ 11,113     $ 29,683  
Accounts receivable, net   6,560       1,666  
Deferred rents receivable   725       1,678  
Notes receivable, current portion   134       127  
Inventory   18,309       9,768  
Investments, current   274       251  
Other current assets   3,768       1,440  
Total current assets   40,883       44,613  
Property and equipment, net   70,396       62,150  
Intangible assets, net   9,469       162  
Goodwill   8,079       2,068  
Notes receivable, net of current   9,160       8,987  
Operating lease right-of-use assets   4,954       5,081  
Finance lease right-of-use assets   747       46  
Other assets   1,010       98  
Total assets $ 144,698     $ 123,205  
       
Liabilities, mezzanine equity and stockholders’ equity      
Current liabilities:      
Mortgages and notes payable, current portion $ 2,825     $ 1,410  
Accounts payable   7,973       5,099  
Accrued expenses and other   3,265       3,149  
Income taxes payable   11,663       16,467  
Operating lease liabilities, current portion   1,284       1,071  
Finance lease liabilities, current portion   241       27  
Total current liabilities   27,251       27,223  
Mortgages and notes payable, net of current   23,048       17,262  
Operating lease liabilities, net of current   4,214       4,574  
Finance lease liabilities, net of current   483       22  
Other liabilities   100       100  
Total liabilities   55,096       49,181  
       
Commitments and contingencies      
       
Mezzanine equity:      
Series B convertible preferred stock   14,725       14,725  
Series C convertible preferred stock   23,000       23,000  
Total mezzanine equity   37,725       37,725  
       
Stockholders’ equity      
Common stock   339       334  
Common stock subscribed but not issued   41       —  
Additional paid-in capital   141,652       134,920  
Accumulated deficit   (88,675 )     (97,392 )
Noncontrolling interests   (1,480 )     (1,563 )
Total stockholders’ equity   51,877       36,299  
Total liabilities, mezzanine equity and stockholders’ equity $ 144,698     $ 123,205  


MariMed Inc.
Condensed Consolidated Statements of Operations
(in thousands, except percentages and per share amounts)
(unaudited)

  Three months ended   Nine months ended
  September 30,   September 30,
    2022       2021       2022       2021  
               
Revenue $ 33,912     $ 33,208     $ 98,180     $ 90,420  
Cost of revenue   17,748       15,027       50,035       39,647  
Gross profit   16,164       18,181       48,145       50,773  
               
Gross margin   47.7 %     54.7 %     49.0 %     56.2 %
               
Operating expenses:              
Personnel   3,746       1,481       10,170       5,266  
Marketing and promotion   1,402       563       2,854       1,058  
General and administrative   5,097       9,481       16,890       16,934  
Acquisition-related and other   143       —       897       —  
Bad debt   40       36       54       1,855  
Total operating expenses   10,428       11,561       30,865       25,113  
               
Income from operations   5,736       6,620       17,280       25,660  
               
Interest and other (expense) income:              
Interest expense   (518 )     (300 )     (1,271 )     (2,077 )
Interest income   239       26       720       96  
Other (expense) income, net   (251 )     (214 )     24       (631 )
Total interest and other expense   (530 )     (488 )     (527 )     (2,612 )
               
Income before income taxes   5,206       6,132       16,753       23,048  
Provision for income taxes   2,484       4,009       7,894       9,026  
               
Net income   2,722       2,123       8,859       14,022  
Less: Net income attributable to noncontrolling interests   16       103       142       289  
Net income attributable to common stockholders $ 2,706     $ 2,020     $ 8,717     $ 13,733  
               
Net income per share attributable to common stockholders:              
Basic $ 0.01     $ 0.01     $ 0.03     $ 0.04  
Diluted $ 0.01     $ 0.01     $ 0.02     $ 0.04  
               
Weighted average common shares outstanding:              
Basic   339,025       329,454       337,111       324,340  
Diluted   381,071       378,934       379,868       370,204  


MariMed Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

  Nine months ended
  September 30,
    2022       2021  
Cash flows from operating activities:      
Net income attributable to common stockholders $ 8,717     $ 13,733  
Net income attributable to noncontrolling interests   142       289  
Adjustments to reconcile net income to cash provided by operating activities:      
Depreciation and amortization of property and equipment   2,469       1,499  
Amortization of intangible assets   854       518  
Stock-based compensation   6,396       7,152  
Amortization of standalone warrant issuances   —       776  
Amortization of warrants attached to debt   —       539  
Amortization of beneficial conversion feature   —       177  
Amortization of original issue discount   —       52  
Bad debt expense   54       1,855  
Obligations settled with common stock   637       375  
Loss on obligations settled with equity   —       3  
Gain on sale of investment   —       (309 )
Loss on changes in fair value of investments   930       937  
Other investment income   (954 )     —  
Changes in operating assets and liabilities:      
Accounts receivable, net   (4,856 )     (3,886 )
Deferred rents receivable   111       192  
Inventory   (4,215 )     (4,163 )
Other current assets   (1,973 )     (1,641 )
Other assets   (113 )     (17 )
Accounts payable   2,372       2,098  
Accrued expenses and other   (193 )     8,069  
Income taxes payable   (4,804 )     —  
Net cash provided by operating activities   5,574       28,248  
       
Cash flows from investing activities:      
Purchases of property and equipment   (9,985 )     (14,649 )
Business acquisitions, net of cash acquired   (12,746 )     —  
Advances toward future business acquisitions   (800 )     —  
Purchases of cannabis licenses   (330 )     (638 )
Proceeds from sale of investment   —       1,475  
Proceeds from notes receivable   130       407  
Net cash used in investing activities   (23,731 )     (13,405 )
       
Cash flows from financing activities:      
Proceeds from issuance of preferred stock   —       23,000  
Equity issuance costs   —       (387 )
Proceeds from issuance of promissory notes   —       35  
Principal payments of mortgages and promissory notes   (1,033 )     (16,248 )
Proceeds from mortgages   3,000       2,700  
Proceeds from exercise of stock options   10       31  
Proceeds from exercise of warrants   —       93  
Repayment of loans from related parties   —       (1,158 )
Principal payments of finance leases   (166 )     (26 )
Redemption of minority interests   (2,000 )     —  
Distributions   (224 )     (301 )
Net cash (used in) provided by financing activities   (413 )     7,739  
       
Net (decrease) increase in cash and cash equivalents   (18,570 )     22,582  
Cash and equivalents, beginning of year   29,683       2,999  
Cash and cash equivalents, end of period $ 11,113     $ 25,581  


MariMed Inc.
Reconciliation of Non-GAAP and GAAP Financial Measures
(in thousands, except percentages)
(unaudited)

  Three months ended   Nine months ended
  September 30,   September 30,
    2022       2021       2022       2021  
Non-GAAP Adjusted EBITDA              
GAAP Net income $ 2,722     $ 2,123     $ 8,859     $ 14,022  
Interest expense, net   279       274       551       1,981  
Income tax provision   2,484       4,009       7,894       9,026  
Depreciation and amortization of property and equipment   917       536       2,469       1,499  
Amortization of acquired intangible assets   429       172       854       518  
EBITDA (earnings before interest, taxes, depreciation and amortization)   6,831       7,114       20,627       27,046  
Stock-based compensation   1,372       5,552       6,396       7,152  
Settlement of litigation   —       (266 )     —       (266 )
Acquisition-related and other   143       —       897       —  
Other expense (income), net   251       214       (24 )     631  
Adjusted EBITDA $ 8,597     $ 12,614     $ 27,896     $ 34,563  
               
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)              
GAAP Net income   8.0 %     6.4 %     9.0 %     15.5 %
Interest expense, net   0.8 %     0.8 %     0.6 %     2.2 %
Income tax provision   7.3 %     12.1 %     8.0 %     9.9 %
Depreciation and amortization of property and equipment   2.7 %     1.6 %     2.5 %     1.7 %
Amortization of acquired intangible assets   1.3 %     0.5 %     0.9 %     0.6 %
EBITDA margin   20.1 %     21.4 %     21.0 %     29.9 %
Stock-based compensation   4.1 %     16.8 %     6.5 %     7.9 %
Settlement of litigation   — %     (0.8 %)     0.9 %     (0.3 %)
Acquisition-related and other   0.4 %     — %     — %     — %
Other expense (income), net   0.8 %     0.6 %     — %     0.7 %
Adjusted EBITDA margin   25.4 %     38.0 %     28.4 %     38.2 %


MariMed Inc.
Supplemental Information
Revenue Components
(in thousands)
(unaudited)

  Three months ended   Nine months ended
  September 30,   September 30,
    2022     2021     2022     2021
Product revenue:              
Product revenue - retail   23,593     23,454     68,121     59,230
Product revenue - wholesale   9,009     6,633     23,029     20,536
Total product revenue   32,602     30,087     91,150     79,766
Other revenue   1,310     3,121     7,030     10,654
Total revenue $ 33,912   $ 33,208   $ 98,180   $ 90,420

Primary Logo

Source: MariMed Inc.

Released November 7, 2022